MarketCap
Facebook
X
TelegramGeschäftsbericht 2024
hinzugefügt 11.04.2026
Genfit SA EV 2011-2026 | GNFT
EV Jährlich Genfit SA
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 168 B | 229 M | 600 M | 1.3 M | -84.9 M | 23.4 M | 13.8 M | 15.9 M | 15.1 M | 16.7 M | 24.6 M |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 168 B | -84.9 M | 15.3 B |
EV anderer Aktien in der Pharmaeinzelhändler
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
82.6 M | $ 8.64 | 8.07 % | $ 85.4 M |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
-28.9 M | $ 3.66 | -1.48 % | $ 8.81 B |  Australia |
 |
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-55.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M |  France |
 |
Applied Therapeutics
APLT
|
563 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-1.76 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
1.92 B | $ 21.36 | 4.86 % | $ 998 M | USA |
 |
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
125 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
493 M | $ 1.47 | 5.0 % | $ 378 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | USA |
 |
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 2.92 | - | $ 4.81 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
540 M | $ 4.19 | 2.7 % | $ 448 M | USA |
 |
Aravive
ARAV
|
58.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
3.64 B | $ 24.12 | -0.37 % | $ 3.07 B | USA |
 |
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
2.07 B | $ 32.59 | 1.09 % | $ 2.16 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
629 M | $ 1.47 | -1.34 % | $ 391 M | Britain |
 |
Aptose Biosciences
APTO
|
36.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
9.99 M | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
-35.4 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
59.6 B | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-720 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
79.3 B | $ 4.25 | 8.35 % | $ 286 B | Britain |
 |
Allena Pharmaceuticals
ALNA
|
-14.1 M | - | 3.16 % | $ 1.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
1.16 B | $ 2.22 | 2.3 % | $ 461 M | USA |
 |
Evogene Ltd.
EVGN
|
-4.88 M | $ 0.82 | 1.13 % | $ 27.9 M | Israel |
 |
Baudax Bio
BXRX
|
29.8 M | - | 0.59 % | $ 63 K | USA |
 |
Cabaletta Bio
CABA
|
253 M | $ 3.2 | 2.24 % | $ 322 M | USA |
 |
Alpine Immune Sciences
ALPN
|
363 M | - | - | $ 2.17 B | USA |
 |
CymaBay Therapeutics
CBAY
|
3.36 B | - | - | $ 3.45 B | USA |
 |
Aileron Therapeutics
ALRN
|
4.02 M | - | 10.36 % | $ 9.8 M | USA |